HER2-TARGETED THERAPIES

This review article provides an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long‐term follow‐up strategies for patients at risk of experiencing cancer therapy‐related cardiotoxicities

This position statement reviews the use of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging, and computed tomography in the management of cancer patients based on current evidence for the value of modern cardiovascular imaging in the cardio‐oncology field, and discusses future directions and ongoing cardiovascular imaging research.

This position statement presents evidence‐based risk stratification tools for oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities.

The most recent update to the NCCN Survivorship guidelines has added a new algorithm for cardiovascular disease risk assessment among cancer survivors, which includes the ABCDEs to Promote Cardiovascular Wellness (SCVD-1 and SCVD-1).

This review article explores the links between cancer, cancer treatment, and cardiovascular risk, including mechanisms associated with cardiotoxicity, screening and surveillance for patients undergoing cancer treatment, and effective preventative and management strategies used to reduce the incidence of cardiotoxicities in patients receiving chemotherapeutics or radiation.

This curated resource from the American College of Cardiology offers links to cardio-oncology news and JACC journal articles, education and meeting opportunities, and tools and practice support for clinicians.

Through this webpage, the International Cardio-Oncology Society provides myriad resources to help both clinicians and patients stay aware and informed about the latest in cardio-oncology.

This detailed resource from the Australian Cancer Institute NSW provides information on prevention, assessment, and management of cardiac toxicity associated with HER2-targeted therapies, and more.

This Viewpoint article highlights the importance of reconsidering certain clinical visits, including imaging tests, for patients with cancer and/or cardiovascular disease during the ongoing COVID-19 pandemic. The authors also provide general guidance, based on available evidence, regarding the role of routine cardiac surveillance as the novel coronavirus continues to be a threat.

Developed by an American Society of Clinical Oncology expert panel and based on a systematic review of literature, these guidelines equip health care providers to discuss potential cardiac dysfunction with patients at high risk and initiate appropriate prevention and screening measures prior to beginning therapy.

Learn from the multidisciplinary team of cardio-oncology specialists at Memorial Sloan Kettering Cancer Center about how to balance the anticipated benefits of breast cancer therapy with cardiovascular risk and helpful strategies to prevent cardiotoxicity and improve outcomes and long-term quality of life for breast cancer survivors.

This comprehensive review from Breast Cancer Research and Treatment analyses clinical trials of trastuzumab, lapatinib, pertuzumab, T-DM1, and neratinib in breast cancer. The authors discuss incidence and mechanisms for cardiotoxicity of HER2-targeted therapies, in addition to summarizing practices in management of cardiotoxicity for routine patient care.

Stay up to date about emerging research on the cardiotoxicities seen with many types of cancer therapy. Learn about why these cardiac effects occur, and how to best monitor for and manage them in your patients. 

Learn about the development and implementation of a cardio-oncology program in a suburban community cardiology practice, created to provide service in this area to breast cancer patients at risk for cardiotoxicity, including the use of the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework to guide the project and enhance the translation of research into practice through planning and execution.

This review explores current data on risk factors, diagnoses, and treatment options that impact cardio-oncologic patients with COVID-19, in addition to offering strategies for the treatment and management of this population.

The patient section of the Canadian Cardiac Oncology Network’s site offers patients access to information about cardiac oncology, including educational resources, clinical trials, and research articles, in addition to a frequently asked questions list and Canadian-specific clinic search.

This resource provides a click-through and searchable listing of cancer drugs, their drug class and cancer indications, and their associated cardio-toxicities, to help clinicians stay informed when treating their patients.

This JADPRO article highlights current and emerging data on HER2-directed therapies and outlines strategies for managing adverse events—including cardiotoxicity.

Find guidance on managing various cardiotoxicities associated with HER2-targeted therapies approved for the treatment for breast cancer.

This patient-focused webpage provides information on the different types of HER2-targeted therapies and associated cardiovascular concerns.

Review this article geared to clinicians for up-to-date information on the cardiotoxicities associated with trastuzumab and other HER2-targeted therapies